South Dakota Investment Council Sells 12,842 Shares of Zimmer Biomet Holdings, Inc. $ZBH

South Dakota Investment Council lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 5.6% during the third quarter, Holdings Channel reports. The institutional investor owned 214,843 shares of the medical equipment provider’s stock after selling 12,842 shares during the quarter. South Dakota Investment Council’s holdings in Zimmer Biomet were worth $19,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in ZBH. Sompo Asset Management Co. Ltd. bought a new position in shares of Zimmer Biomet during the 3rd quarter worth $227,000. Brickwood Asset Management LLP raised its stake in Zimmer Biomet by 15.0% in the 3rd quarter. Brickwood Asset Management LLP now owns 11,362 shares of the medical equipment provider’s stock valued at $1,009,000 after acquiring an additional 1,486 shares during the period. Ironwood Investment Counsel LLC bought a new stake in Zimmer Biomet in the 3rd quarter valued at about $205,000. Edgestream Partners L.P. bought a new stake in Zimmer Biomet in the 3rd quarter valued at about $1,971,000. Finally, Minneapolis Portfolio Management Group LLC lifted its holdings in Zimmer Biomet by 2.8% during the third quarter. Minneapolis Portfolio Management Group LLC now owns 300,988 shares of the medical equipment provider’s stock valued at $26,737,000 after purchasing an additional 8,189 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by insiders.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $102.17 on Wednesday. The stock has a market cap of $19.34 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 2.38 and a beta of 0.50. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $112.54. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.79 and a current ratio of 1.46. The stock has a fifty day moving average of $96.00 and a 200-day moving average of $92.73.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.90 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.56 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s payout ratio is presently 24.30%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZBH shares. UBS Group upped their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Argus reissued a “buy” rating and issued a $125.00 price target on shares of Zimmer Biomet in a research report on Thursday, October 22nd. BMO Capital Markets dropped their price target on shares of Zimmer Biomet from $102.00 to $101.00 and set a “market perform” rating on the stock in a research note on Monday. Finally, Truist Financial set a $114.00 price objective on shares of Zimmer Biomet in a report on Thursday, November 5th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $114.32.

Check Out Our Latest Stock Analysis on ZBH

Latest Zimmer Biomet News

These are some of the ZBH news items that stood out recently:

  • Positive Sentiment: Wells Fargo upgraded ZBH from “equal weight” to “overweight” and raised its price target to $123 from $113, citing the opportunity associated with the Monogram orthopedic robot. The new target implies about 20% upside from the cited share price. Zimmer Biomet upgraded at Wells Fargo on Monogram orthopedic robot
  • Positive Sentiment: Stifel raised its price target to $140 from $125 and reiterated a “buy” rating, signaling substantial potential upside in its view. Zimmer Biomet price target raised to $140 at Stifel
  • Negative Sentiment: BMO Capital Markets trimmed its target to $101 from $102 and maintained a “market perform” rating, reflecting a more guarded view and limited upside at the cited share price.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

Further Reading

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.